Participation of purines in the modulation of inflammatory response in rats experimentally infected by Cryptococcus neoformans

Microbial Pathogenesis

Volumn 99, Issue , 2016, Pages 36-40

  de Azevedo, Maria Isabel ^a,c   Ferreiro, Laerte ^a   Da Silva, Aleksandro S ^b   Tonin, Alexandre A ^c   Monteiro, Danieli Urach ^c   Casali, Emerson A ^a,d   Moritz, Cesar E J ^a   Schirmbeck, Gabriel H ^a   Cardoso, Valesca V ^a,d   Flores, Mariana M ^c   Fighera, Rafael ^c   Stefani, Lenita M ^b   Santurio, Janio M ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b SANTA CATARINA STATE UNIVERSITY   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^d CENTRO UNIVERSITÁRIO METODISTA IPA   (Brazil)

Author keywords

Cryptococcosis; Immune response; Pathology; Purinergic signaling

Indexed keywords

ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; HYPOXANTHINE; INOSINE; PURINE; URIC ACID; XANTHINE; IMMUNOLOGIC FACTOR; PURINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APATHY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; HISTOPATHOLOGY; INFLAMMATION; LUNG LESION; MALE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; CHEMISTRY; CRYPTOCOCCUS NEOFORMANS; DISEASE MODEL; PATHOGENICITY; PATHOLOGY; SERUM; TIME FACTOR; WISTAR RAT;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; INFLAMMATION; PURINES; RATS, WISTAR; SERUM; TIME FACTORS;

EID: 84982823077     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2016.07.015     Document Type: Article

References (31)

1. [1] Cryptococosis, Negroni R., Clin. Dematology 30 (2012), 599–609.
2. [2] Christianson, J.C., Engber, W., Andes, D., Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med. Mycol. 41 (2003), 177–188.
3. [3] El-Kersh, K., Rawasia, W.F., Chaddha, U., et al. Rarity revisited: cryptococcal peritonitis. BMJ Case Rep., 10, 2013.
4. [4] Goldman, D.L., Lee, S.C., Mednick, A.J., et al. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellularparasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect. Immun. 68 (2000), 832–838.
5. [5] Bovers, M., Hagen, F., Boekhout, T., Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev. Iberoam. Micol. 25 (2008), S4–S12.
6. [6] Ralevic, V., Burnstock, G., Receptores for purines and pyrimidines. Pharmacol. Rev. 50 (1998), 413–492.
7. [7] Sitkovsky, M.V., Ohta, A., The ‘danger’ sensors that STOP the immune response: the A2 adenosine receptors?. Trends Immunol. 26 (2005), 299–304.
8. [8] Burnstock, G., Purinergic signaling – an overview. Novartis Found. Symp. 276 (2006), 26–48.
9. [9] Desrosiers, M.D., Cembrola, K.M., Fakir, M.J., et al. Adenosine deamination sustains dendritic cell activation in inflammation. J. Immunol. 179 (2007), 1884–1892.
10. [10] Jin, X., Shepherd, R.K., Duling, B.R., et al. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. Am. Soc. Clin. Investigation 100 (1997), 2849–2857.
11. [11] Gounaris, K., Selkirk, M.E., Parasite nucleotide-metabolizing enzymes and host purinergic signalling. Trends Parasitol. 21 (2005), 17–21.
12. [12] Chen, X.B., Gomes, M.J., Estimation of Microbial Protein Supply to Sheep and Cattle Based on Urinary Excretion of Purine Derivatives an Overview of Technical Details. Occasional Publication, International Feed Research Unit. 1992, Rowett Research Institute, Aberdeen, UK.
13. [13] Martins, D.B., Zanette, R.A., Françs, R.T., et al. Massive cryptococcal disseminated infection in an immunocompetent cat. Veterinary Dermatol. 22 (2010), 232–234.
14. [14] Goldman, D., Lee, S.C., Casadevall, A., Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62 (1994), 4755–4761.
15. [15] Ryder, J.M., Determination of adenosine triphosphate and its breakdown products in fish products by high-performance liquid chromatography. J. Agric. Food Chem. 33 (1985), 678–680.
16. [16] Voelter, W., Zech, K., Arnold, P., et al. Determination of selected pyrimidines, purines and their metabolites in serum and urine by reversed-phase ionpair chromatography. J. Chromatogr. 199 (1980), 345–354.
17. [17] Bours, M.J., Swennen, E.L.D.I., Virgilio, F., et al. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112 (2006), 358–404.
18. [18] Gandelman, M., Peluffo, H., Beckman, J.S., et al. Research Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J. Neuroinflammation 7 (2010), 9–33.
19. [19] Bot, A., Editorial –in this issue: innate immunity in normal and pathologic circumstances. Int. Rev. Immunol. 33 (2014), 441–442.
20. [20] Haskó, G., Németh, Z.H., Vizi, E.S., et al. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-g production and prevents lethality inendotoxemic mice. Eur. J. Pharmacol. 358 (1998), 261–268.
21. [21] Haskó, G., Kuhel, J.F., Chen, M.A., et al. Adenosine inhibits IL-12 and TNF- production via adenosine A2A receptor-dependent and independent mechanisms. FASEB J. 14 (2000), 2065–2074.
22. [22] Link, A.A., Kino, T., Worth, J.A., et al. Ligand-activation of the adenosine A2A receptors inhibits IL-12 production by human monocytes. J. Immunol. 164 (2000), 436–442.
23. [23] Khoa, N.D., Montesinos, M.C., Reiss, A.B., et al. Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells. J. Immunol. 167:7 (2001), 4026–4032.
24. [24] Le Moine, O., Stordeur, P., Schandene, L., et al. Adenosine enhances IL-10 secretion by human monocytes. J. Immunol. 156 (1996), 4408–4414.
25. [25] Haskó, G., Szabo, C., Nemeth, Z.H., et al. Adenosine receptor agonists differentially regulate IL-10, TNF-, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157 (1996), 4634–4640.
26. [26] Azevedo, M.I., Ferreiro, L., Da Silva, A.S., et al. E-NTPDase and E-ADA activities in rats experimental infected by Cryptococcus neoformans. Veterinary Microbiol. 174 (2014), 206–213.
27. [27] Franco, R., Casado, V., Ciruela, F., et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog. Neurobiol. 52 (1997), 283–294.
28. [28] Haskó, G., Cronstein, B.N., Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25 (2004), 33–39.
29. [29] Scott, G.S., Spitsin, S.V., Kean, R.B., et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. PNAS, Proc.eedings of the National Academy of Sciences USA, 99, 2002, 16303–16308.
30. [30] Ralevic, V., Burnstock, G., Involvement of purinergic signalling in cardiovascular diseases. Drug News Perspect. 16 (2003), 133–140.
31. [31] Santos, C.X., Anjos, E.I., Augusto, O., Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Archives Biochem. Biophysics 372 (1999), 285–294.